SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 th Annual ROTH Conference,
SAN DIEGO, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share.
Biocept Appoints Michael Nall as CEO Biocept, Inc. announced today that it has appointed Michael W. Nall as President and Chief Executive Officer. Mr. Nall’s extensive commercialization, sales and marketing experience will be a significant asset as the company brings its pipeline of OncoCEETM
MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients with HER2- Tumors by Tissue Analysis San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) and
Biocept to Present Clinical Findings on Circulating Tumor Cells (CTCs) at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting San Diego, California – Biocept, Inc., a CLIA-certified laboratory testing company focused on oncology diagnostics, specifically the detection and analysis
Biocept to Present at the 103rd AACR Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on
Biocept to present at Molecular Tri-Conference on Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its
Clarient, Inc., a GE company, announces the launch of Biocept’s proprietary Circulating Tumor Cells (CTC) test for HER2 status in breast cancer patient San Diego and Aliso Viejo, California: – Biocept, Inc., a privately-held laboratory services company focused on Circulating Tumor Cells (CTCs), and
